Dear All,
Welcome to the Bulletin 13 from the HSE National Immunisation Office which highlights changes in clinical guidance for the COVID-19 vaccination programme.
In this edition we cover
- Updated product information for COVID-19 Vaccine AstraZeneca®
- EMA COVID-19 Vaccine AstraZeneca®: review of very rare cases of unusual blood clots continues
- Vaccination in different settings
- Remember before administering a COVID-19 vaccine
- Lymphadenopathy after COVID-19 vaccines
- NIAC Update on COVID-19 Vaccine Prioritisation Groups
- HSE National Cold Chain Service
- Medical Product Alert N ° 2/2021: Falsified COVID-19 Vaccine CRM:0408811 identified in the WHO Region of the Americas
- Public Health Advice should still be followed after vaccination
- Benefits of COVID-19 Vaccines in the prevention of SARS-CoV 2 infection
- CDC study confirms protective benefits of mRNA COVID-19 Vaccines
- Vaccine effectiveness of the first dose of AstraZeneca and Pfizer/BioNTech Vaccines against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)
- Delayed reactions to mRNA-1273 (Moderna) Vaccine
- HSE Website Update
- CoVax System Update
- COVID-19 Vaccination Training Programme
- Website
- Where to send queries
We also recommend you visit our website as new documents have been added and updates have been made to the existing clinical documents.
Please share this update with your colleagues to ensure everyone has access to the most up to date information.
Finally a reminder bulletins will be published every week or more frequently, if required.
National Immunisation Office